Late Thursday, Taiho Oncology, Taiho Pharmaceutical, And Cullinan Oncology Launched Rezilient3 Phase 3 Trial Of Zipalertinib Plus Chemotherapy As Potential First-line Treatment For Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Portfolio Pulse from Benzinga Newsdesk
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Oncology have launched the Rezilient3 Phase 3 trial of Zipalertinib plus chemotherapy as a potential first-line treatment for non-small cell lung cancer harboring EGFR Exon 20 insertion mutations.
August 04, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cullinan Oncology, listed as CGEM, is part of the team launching the Rezilient3 Phase 3 trial for a potential new lung cancer treatment.
Cullinan Oncology, listed as CGEM, is directly involved in the launch of the Rezilient3 Phase 3 trial. This could potentially lead to a new first-line treatment for non-small cell lung cancer, which could significantly impact the company's standing and profitability in the oncology market. This news is highly relevant and important for CGEM investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100